Resources from the same session
4028 - TROPHIMMUN, a 2 cohort phase II trial of the anti-PD-L1 monoclonal antibody avelumab in chemo-resistant gestational trophoblastic neoplasia (GTN) patients: preliminary outcomes in cohort A.
Presenter: Benoit You
Session: Poster Discussion session - Gynaecological cancers
Resources:
Abstract
3750 - Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer
Presenter: Ana Oaknin
Session: Poster Discussion session - Gynaecological cancers
Resources:
Abstract
Poster Discussion session - Gynaecological cancers - Invited Discussant LBA35 and 935PD
Presenter: Mansoor Raza Mirza
Session: Poster Discussion session - Gynaecological cancers
Resources:
Slides
Webcast
4294 - Association of PD-L1 Expression and Gene Expression Profiling With Clinical Response to Pembrolizumab in Patients With Advanced Recurrent Ovarian Cancer: Results From the Phase 2 KEYNOTE-100 Study
Presenter: Jonathan Ledermann
Session: Poster Discussion session - Gynaecological cancers
Resources:
Abstract
Slides
2452 - A phase 2 study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)
Presenter: Jung-Min Lee
Session: Poster Discussion session - Gynaecological cancers
Resources:
Abstract
2179 - A phase 2 trial of combination nivolumab and bevacizumab in recurrent ovarian cancer.
Presenter: Joyce Liu
Session: Poster Discussion session - Gynaecological cancers
Resources:
Abstract
Poster Discussion session - Gynaecological cancers - Invited Discussant LBA36, 936PD and 937PD
Presenter: Antonio González Martín
Session: Poster Discussion session - Gynaecological cancers
Resources:
Slides
Webcast
2339 - Quality of life and symptoms in longterm survivors with ovarian cancer: It’s still an issue. Expression VI – Carolin meets HANNA – Holistic Analysis of Long-term survival with Ovarian Cancer: the international NOGGO, ENGOT and GCIG survey
Presenter: Hannah Woopen
Session: Poster Discussion session - Gynaecological cancers
Resources:
Abstract
3678 - A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: Blinded pooled interim safety data from the PRIMA Study
Presenter: Antonio Gonzalez
Session: Poster Discussion session - Gynaecological cancers
Resources:
Abstract
Poster Discussion session - Gynaecological cancers - Invited Discussant 939PD and 941PD
Presenter: Nicoletta Colombo
Session: Poster Discussion session - Gynaecological cancers
Resources:
Slides
Webcast